Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (≥3.0 and <10.0 ng/ml)

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3159-3166

  Karamanolakis, Dimitrios ^a   Lambou, Theocharis ^b   Bogdanos, John ^a   Milathianakis, Constantine ^a,c   Sourla, Antigone ^a,d   Lembessis, Peter ^a,d   Halapas, Antonis ^a   Pissimissis, Nicholas ^a   Dessypris, Nick ^a   Petridou, Eleni Th ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THRIASIO GENERAL HOSPITAL   (Greece)

^c Urology Clinic   (Greece)

^d Diagnostic Genetic Center   (Greece)

Author keywords

Prostate cancer risk; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ENANTATE;

ADULT; AGED; ARTICLE; BIOPSY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 33746706821     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Labrie F, Dupont A, Suburu R et al: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147: 846-851; discussion 851-842, 1992.
2. Labrie F, Dupont A, Suburu R et al: Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med 16: 425-439, 1993.
3. Catalona WJ, Partin AW, Slawin KM et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 279: 1542-1547, 1998.
4. Zlotta A and Schulman C: Cancer of the prostate: advances in the use of PSA and its derived indices - new tumor markers. Rev Med Brux 20: A201-205, 1999.
5. Beemsterboer PM, Kranse R, de Koning HJ et al: Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 84: 437-441, 1999.
6. Candas B, Cusan L, Gomez JL et al: Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 45: 19-35, 2000.
7. Catalona WJ, Ramos CG, Carvalhal GF et al: Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 55: 791-795, 2000.
8. Jung K, Lein M, Butz H et al: New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. J Urol 175: 1275-1280, 2006.
9. Purifoy FE, Koopmans LH and Mayes DM: Age differences in serum androgen levels in normal adult males. Hum Biol 53: 499-511, 1981.
10. Morley JE, Kaiser F, Raum WJ et al: Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 94: 7537-7542, 1997.
11. Morales A and Tenover JL: Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urol Clin North Am 29: 975-982, x, 2002.
12. Lund BC, Bever-Stille KA and Perry PJ: Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 19: 951-956, 1999.
13. Basaria S and Dobs AS: Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 15: 131-142, 1999.
14. Derouet H, Lehmann J, Stamm B et al: Age dependent secretion of LH and ACTH in healthy men and patients with erectile dysfunction. Eur Urol 41: 144-153; discussion 153-144, 2002.
15. Jackson JA, Waxman J and Spiekerman AM: Prostatic complications of testosterone replacement therapy. Arch Intern Med 149: 2365-2366, 1989.
16. Morgentaler A, Bruning CO 3rd and DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. Jama 276: 1904-1906, 1996.
17. Loughlin KR and Richie JP: Prostate cancer after exogenous testosterone treatment for impotence. J Urol 157: 1845, 1997.
18. Ferri M and Norman RW: Prostate cancer in a hypogonadal male receiving androgen supplementation. Can J Urol 7: 1055-1056, 2000.
19. Rhoden EL and Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350: 482-492, 2004.
20. Snyder PJ, Peachey H, Hannoush P et al: Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84: 1966-1972, 1999.
21. van den Beld AW, de long FH, Grobbee DE et al: Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85: 3276-3282, 2000.
22. Ferrando AA, Sheffield-Moore M, Yeckel CW et al: Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 282: E601-607, 2002.
23. Morales A: Androgen replacement therapy and prostate safety. Eur Urol 41: 113-120, 2002.
24. Morgentaler A, Bruning CO III and DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. JAMA 276: 1904-1906, 1996.
25. No author: Screening for prostate cancer: recommendation and rationale. Ann Intern Med 137: 915-916, 2002.
26. Barry MJ: Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344: 1373-1377, 2001.
27. Carter HB, Pearson JD, Waclawiw Z et al: Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 45: 591-596, 1995.
28. Ornstein DK, Rao GS, Smith DS et al: Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol 157: 195-198, 1997.
29. Wald NJ, Watt HC, George L et al: Adding free to total prostate-specific antigen levels in trials of prostate cancer screening. Br J Cancer 82: 731-736, 2000.
30. Okegawa T, Noda H, Ohta M et al: Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer. Int J Urol 8: 438-443, 2001.
31. Carter HB, Pearson JD, Metter EJ et al: Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 27: 25-31, 1995.
32. Hulka BS, Hammond JE, Di Ferdinande G et al: Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate 11: 171-182, 1987.
33. Harper ME, Pierrepoint CG and Griffiths K: Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20: 477-482, 1984.
34. Hoffman MA, DeWolf WC and Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163: 824-827, 2000.
35. Prehn RT: On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 59: 4161-4164, 1999.